Results 261 to 270 of about 74,021 (384)

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly   +17 more
wiley   +1 more source

The TRIP database showed most Acute Respiratory Infections questions were already addressed by Cochrane reviews [PDF]

open access: yes, 2019
Brassey, Jon   +4 more
core   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska   +8 more
wiley   +1 more source

C1 esterase inhibitor (C1-INH) response as a supportive diagnostic criterion for patients with suspected hereditary angioedema with normal C1-INH. [PDF]

open access: yesWorld Allergy Organ J
Smith AM   +11 more
europepmc   +1 more source

Understanding Nurses' Needs Regarding Tailored, Evidence‐Based Sleep Education and Training

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim Identify desired training content for shift‐working nurses to improve their sleep and fatigue. Design A descriptive qualitative design. Methods We recruited night shift nurses (N = 23) to provide feedback during virtual focus groups/interviews. Data collection occurred in the U.S. between March and June 2024.
Beverly M. Hittle   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy